mebeverine / Generic mfg. - LARVOL DELTA

Evaluation of safety and efficacy of the combination of mebeverine and sulpiride in treatment of patients with functional gastrointestinal disorders: A prospective cohort. (PubMed, J Int Med Res) - "Among 253 patients, 227 patients (89.72%, 95% confidence interval: 85.96%-93.49%) demonstrated ≥50% improvement in the tailored gastrointestinal symptoms rating scale total score, whereas 26 (10.28%) did not report any improvement. In terms of safety, 2 (0.79%) patients reported diarrhea, 1 (0.4%) had mild dyspepsia, and 1 (0.4%) had galactorrhea.ConclusionOur results suggest that the combination of mebeverine and sulpiride may represent a safe and effective treatment option for patients with functional gastrointestinal disorders."

Clinical • Journal • Dyspepsia • Gastroenterology • Gastrointestinal Disorder • Pain

Vascular Pharmacology Patent on Mebeverine. (PubMed, Curr Cardiol Rev) - No abstract available

Journal • Cardiovascular

Development and evaluation of chitosan-xanthan gum-based controlled release nanoparticles of mebeverine hydrochloride for targeted IBS therapy: in silico, in vitro, and in vivo investigations. (PubMed, Daru) - "The chitosan-xanthan gum nanoparticle system enabled sustained, colon-specific delivery of mebeverine hydrochloride with superior therapeutic efficacy in vivo, offering a promising strategy for long-term IBS management."

Journal • Preclinical • Gastrointestinal Disorder • Immunology

Smart bioconjugated MOFs for targeted drug delivery: Albumin and globulin effects on mebeverine release dynamics. (PubMed, Nanomedicine) - "However, neither formulation performed optimally at physiological pH (7.4), which may require further formulation optimization. These findings support TF-GLB as a promising oral delivery system for IBS."

Journal • Gastrointestinal Disorder • Pain

Dual Extrusion-based 3D-Printed Core-Shell Tablets for Colorectal Delivery of Mebeverine Hydrochloride. (PubMed, Drug Dev Ind Pharm) - "Moreover, FTIR spectrums showed no unwanted chemical interactions, TGA and DSC analysis verified the thermal stability the drug and excipients at printing temperatures. The dual extrusion based-3D printing of drug-loaded hydrogel and thermoplastic polymers provides a promising delayed-release single dosage to deliver of thermo- and acid-labile drugs for the management of IBS and associated gastrointestinal disorders."

Journal • Gastroenterology • Gastrointestinal Disorder

Analysis of "Mebeverine and the Influence of Labeling in Adolescents With Irritable Bowel Syndrome or Functional Abdominal Pain Not Otherwise Specified: A 2 × 2 Randomized, Placebo-Controlled Trial". (PubMed, Gastroenterology) - No abstract available

Journal • Gastrointestinal Disorder • Pain

SIGNS, SYMPTOMS, TESTS AND PRESCRIPTIONS RECORDED IN THE YEAR PRIOR TO THE DIAGNOSIS OF EARLY-ONSET COLORECTAL CANCER IN THE UNITED KINGDOM (UEGW 2025) - "Prescriptions for symptomatic treatments such as dibucaine, butylscopolamine, lactulose, mebeverine, and loperamide were also observed in 3.3-7.7% of cases (RRI of 4.8 to 11.8) across the datasets. Signs and symptoms potentially related to CRC were often recorded during the year preceding diagnosis. However, clinical suspicion of CRC remained low in patients under 50, with symptoms frequently attributed to alterative (and potentially co-existing) diagnoses such as haemorrhoids or coeliac disease. While individual symptoms may not always raise clinical concern, combinations of signs, symptoms, and test results could be more informative."

Anemia • Celiac Disease • Colorectal Cancer • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • Solid Tumor

Eluxadoline in Indian Patients With Diarrhoea-Predominant Irritable Bowel Syndrome: A Phase 3, Multicentre, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study [WITHDRAWN] (ACG 2025) - "Composite responder rate at week 12 was 41% (68/166) in Eluxadoline arm and 29.2% (49/168) in Mebeverine arm (p= 0.0238). Treatment difference between arms was 11.8% (1.6%, 22.0%) with lower limit of CI (1.6%) meeting the predefined non-inferiority margin of -12%. The composite responder rate at Week 4 & 8 were 12.0% & 20.5% in Eluxadoline arm and 7.1% & 18.5% in Mebeverine arm respectively."

Clinical • P3 data • Gastrointestinal Disorder

Functionalized Silver Nanoparticles as Multifunctional Agents Against Gut Microbiota Imbalance and Inflammation. (PubMed, Nanomaterials (Basel)) - "The current study aims to assess the antimicrobial and antifungal effects of drug-loaded silver nanoparticles (AgNPs) with previously reported mebeverine analogue (MA) as a potential drug candidate targeting gut microbiota and inflammation in the gastrointestinal tract...Based on the results, drug-loaded AgNPs might be a promising antimicrobial agent, maintaining the MA's potential as a spasmolytic and anti-inflammatory agent. Future in vivo and preclinical experiments will contribute to establishing the in vivo properties of drug-loaded AgNPs."

Journal • Gastrointestinal Disorder • Infectious Disease • Inflammation

Silver Nanoparticles with Mebeverine in IBS Treatment: DFT Analysis, Spasmolytic, and Anti-Inflammatory Effects. (PubMed, Pharmaceutics) - " Based on our results, drug-loaded AgNPs might be a promising medication delivery system for MBH and a useful treatment option for IBS. Future in vivo and preclinical experiments will contribute to the establishment of drug-loaded AgNPs in IBS treatment."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Synthesis, Cytotoxic and Genotoxic Evaluation of Drug-Loaded Silver Nanoparticles with Mebeverine and Its Analog. (PubMed, Pharmaceuticals (Basel)) - " The study underscores the potential of AgNPs as advanced drug delivery systems for safe and significant therapeutic implications for IBS. Future in vivo and preclinical investigations are essential to validate the safe range of exposure doses and evaluation standards for assessing AgNPs' safety in targeted and personalized medicine."

Journal • Gastroenterology • Gastrointestinal Disorder

Mebeverine and the influence of labeling in adolescents with irritable bowel syndrome or functional abdominal pain-NOS: a 2x2 randomized, placebo-controlled trial. (PubMed, Gastroenterology) - "Mebeverine was ineffective in pediatric IBS and FAP-NOS treatment. However, a positive drug label significantly enhanced treatment outcomes compared to a blinded trial label."

Journal • Gastrointestinal Disorder • Pain • Pediatrics

Spasmolytic Activity and Anti-Inflammatory Effect of Novel Mebeverine Derivatives. (PubMed, Biomedicines) - " Three of the tested compounds have emerged as the most active and effective in all the studies conducted. Future in vivo and preclinical experiments will contribute to the establishment of these novel mebeverine derivatives as potential drug candidates against inflammatory diseases in the gastrointestinal tract."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Inflammation • Pain

Development of selective method for identifying mebeverine in hair (PubMed, Sud Med Ekspert) - "The main mebeverine's metabolites have been determined and native mebeverine and its marker metabolites (mebeverine and veratric acids) have been found in urine while taking this medicine in therapeutic doses for medical purposes. The application of enzymatic hydrolysis of hair method allowed to establish that hair tissue accumulates only a native molecule of mebeverine, therefore, only by results of hair analysis it is possible to conclude, if there was pharmacological use of this medicine or psychoactive substances from the group of phenylalkilamines. The effectiveness of enzymatic hydrolysis by hyaluronidase to isolate mebeverine from hair has been shown."

Journal

Efficacy of Sertraline on the Symptoms and Quality of Life in Patients With Irritable Bowel Syndrome: A Single-Blinded and Parallel-Designed Randomized Controlled Trial (ACG 2024) - "The control group patients were treated with Mebeverine 200 mg while the case group received Mebeverine 200 mg and Sertraline 50-200 mg. The individuals in the case group showed a significant decrease in HADS (p< 0.001) and VAS (p=0.001) scores at week eight compared to their counterparts in the control group. The case group also showed a significant increase in two SF-36 domains compared to the control group, including a significant improvement in general mental health (p=0.02) and limitations in usual role activities because of physical problems (p=0.01). This study demonstrated that Sertraline increased the general health and quality of life in individuals with IBS, while also effectively improving their pain symptoms."

Clinical • HEOR • CNS Disorders • Depression • Gastrointestinal Disorder • Mood Disorders • Pain • Psychiatry

Delayed autonomic ganglionopathy following nivolumab therapy in a patient with metastatic melanoma (AGW-GESA 2024) - "Diarrhoea was partially managed by cholestyramine, pancreatic enzymes, loperamide, and domperidone. Abdominal pain was managed with mebeverine in combination with both sublingual and transdermal buprenorphine...Recent follow-up included dose adjustments to fludrocortisone and midodrine... We report a case of delayed autonomic ganglionopathy caused by use of nivolumab monotherapy. As acute and subacute presentations of neurological irAE are rare, and delayed presentations are exceedingly rare, clinicians ought to maintain a high level of suspicion on patients receiving treatment with ICI."

Clinical • Metastases • Amyloidosis • Anorexia • Endocrine Cancer • Gastrointestinal Disorder • Hematological Disorders • Hypotension • Immunology • Melanoma • Neuroendocrine Tumor • Oncology • Pain • Solid Tumor • CRP

Ebastine Versus Mebeverine in IBS Patients (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Guy Boeckxstaens | Trial completion date: Jan 2027 ➔ Jan 2028 | Trial primary completion date: Oct 2026 ➔ Oct 2027

Trial completion date • Trial primary completion date • Gastrointestinal Disorder

2-Amino-N-Phenethylbenzamides for Irritable Bowel Syndrome Treatment. (PubMed, Molecules) - "Mebeverine is an antispasmodic that has been widely used in clinical practice to relieve the symptoms of IBS...The newly synthesized compounds also inhibited the expression of interleukin-1β and stimulated the expression of neuronal nitric oxide synthase (nNOS), and, consequently, nitric oxide (NO) synthesis by neurons of the myenteric plexus. This characterizes the newly synthesized compounds as biologically active relaxants, offering a cleaner and more precise application in pharmacological practice, thereby enhancing their potential therapeutic value."

Journal • Gastroenterology • Gastrointestinal Disorder • Pain • IL1B

Spasmolytic Activity of 1,3-Disubstituted 3,4-Dihydroisoquinolines. (PubMed, Biomedicines) - "Since smooth muscle contractile failure is a characteristic feature of many disorders, in the current paper, we concentrate on the parameters of the spontaneous contractile responses of smooth muscle (SM) cells compared to the well-known drug mebeverine. Two of the newly synthesized substances can be identified as essential modulating regulators and potentially used as therapeutic molecules. One of these molecules also showed significant DPPH antioxidant activity compared to rutin."

Journal • Gastrointestinal Disorder

MEBEVERINE VERSUS PLACEBO IN ADOLESCENTS WITH IRRITABLE BOWEL SYNDROME OR FUNCTIONAL ABDOMINAL PAIN AND THE INFLUENCE OF LABELING: A 2X2 RANDOMIZED CONTROLLED TRIAL (ESPGHAN 2024) - "Mebeverine was not superior compared to placebo for the treatment of pediatric IBS and FAP-NOS. However, a positive drug label enhanced treatment success and adequate relief rates significantly, compared to a neutral label. This may affect the design of future pediatric trials."

Clinical • Gastrointestinal Disorder • Pain • Pediatrics

MEBEVERINE VERSUS PLACEBO IN ADOLESCENTS WITH IRRITABLE BOWEL SYNDROME OR FUNCTIONAL ABDOMINAL PAIN AND THE INFLUENCE OF LABELING: A 2X2 RANDOMIZED CONTROLLED TRIAL. (DDW 2024) - "Mebeverine was not superior compared to placebo for the treatment of pediatric IBS and FAP-NOS. However, being convinced to receive mebeverine enhanced treatment success and adequate relief rates significantly compared to not knowing. This may have implications for future pediatric drug trials."

Clinical • Gastrointestinal Disorder • Pain • Pediatrics

THE EFFICACY OF SEROTONIN NORADRENALINE REUPTAKE INHIBITORS IN IRRITABLE BOWEL SYNDROME: A META-ANALYSIS (DDW 2024) - "Subgroup analyses were conducted based on the types of medication (duloxetine venlafaxine) and treatment regimens(single or combination therapy)...05) compared to the placebo or conventional treatment group (mebeverine)...Conclusions Existing evidence suggests that SNRIs have encouraging efficacy in improving abdominal pain and comorbid anxiety and depression in IBS patients. It is necessary to conduct multicenter RCTs to further evaluate the efficacy indication optimal regimen safety and the therapeutical mechanism of SNRIs in the treatment of IBS patients."

Retrospective data • CNS Disorders • Depression • Fibromyalgia • Gastrointestinal Disorder • Major Depressive Disorder • Mood Disorders • Musculoskeletal Pain • Pain • Psychiatry • Rheumatology

3D-QSAR pharmacophore modeling, virtual screening, molecular docking, MD simulations, in vitro and in vivo studies to identify potential anti-hyperplasia drugs. (PubMed, Biotechnol J) - "Based on MD simulations results, the best two hit molecules, that is, ebastine (Ebs) and mebeverine (Mbv) were selected for in vitro and in vivo antioxidant studies performed in mice. TNF-α and COX pro-inflammatory mediators, biochemical assays, histopathological analyses, and immunohistochemistry observations confirmed the anti-inflammatory response of the selected drugs. Based on these findings, it appeared that Ebs can effectively treat psoriasis-like skin lesions and down-regulate inflammatory responses which was consistent with docking predictions and could potentially be employed for further research on inflammation-related skin illnesses such as psoriasis."

Journal • Preclinical • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • TNFA

Development of selective method for mebeverine detection in blood (PubMed, Sud Med Ekspert) - "It has been revealed that using selective method of sample processing, which consists of aqueous phase extraction at pH=2-4 and enzymatic hydrolysis by papain and hyaluronidase during isolation from blood, is required to detect mebeverine in biological liquids. It has been proven that the native mebeverine is hydrolyzed to veratric (3.4-dimethoxybenzoic) acid and mebeverine alcohol at alkalotic pH value of medium. It has been shown that mebeverine extraction is necessary to study using HPLC-MS/MS, which will allow to avoid the native mebeverine degradation in chromatograph injector as with GC-MS method analysis."

Journal

Molecular docking as a tool for the discovery of novel insight about the role of acid sphingomyelinase inhibitors in SARS- CoV-2 infectivity. (PubMed, BMC Public Health) - "Also, we outlined ASMase structure and underlying mechanisms inhibiting viral entry 40 with the aid of inhibitors of acid sphingomyelinase (FIASMAs). In silico molecular docking analyses of FIASMAs with inhibitors revealed that dilazep (S = - 12.58 kcal/mol), emetine (S = - 11.65 kcal/mol), pimozide (S = - 11.29 kcal/mol), carvedilol (S = - 11.28 kcal/mol), mebeverine (S = - 11.14 kcal/mol), cepharanthine (S = - 11.06 kcal/mol), hydroxyzin (S = - 10.96 kcal/mol), astemizole (S = - 10.81 kcal/mol), sertindole (S = - 10.55 kcal/mol), and bepridil (S = - 10.47 kcal/mol) have higher inhibition activity than the candidate drug amiodarone (S = - 10.43 kcal/mol), making them better options for inhibition."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases